Vasorelaxant Effect of Moroccan Cannabis sativa Threshing Residues on Rat Mesenteric Arterial Bed is Endothelium and Muscarinic Receptors Dependent
Open Access
- 1 January 2023
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 1265103
Abstract
Introduction. Ethanolic fraction of Moroccan Cannabis sativa threshing residues (EFCS) was evaluated for its vasorelaxant activity. The current work aims to identify the active metabolites in the ethanolic fraction of the EFCS and illustrate their mechanism of action. Methods. Free radical scavenging capacity of EFCS was assessed using DPPH method. The EFCS vasodilation activities in phenylephrine‐precontracted isolated rat mesenteric arterial beds were investigated in presence of L‐NAME (nitric oxide synthase inhibitor), indomethacin (cyclooxygenase inhibitor), potassium channel blockers (namely tetraetylamonium, barium chloride, and glibenclamide), and atropine. Nitric oxide vascular release was measured by electron paramagnetic resonance (EPR) using a spin trap in rat aortic rings. Results. EFCS induced dose‐dependent vasorelaxation on mesenteric vascular bed. Incubation of the preparations with L‐NAME, ODQ (a soluble guanylyl cyclase inhibitor), or potassium channel blockers reduced the fall of perfusion pressure caused by EFCS. Endothelial denudation or atropine abolished the EFCS’s vasorelaxant effect, suggesting involvement of muscarinic receptors and endothelium‐relaxing factors. The extract induced nitric oxide release in aortic rings in a similar manner as acetylcholine suggesting an effect of EFCS on the muscarinic receptor and the conductance arteries. Chemical investigation of EFCS identified potential active components namely apigenin and derivatives of luteolin skeleton and also additional components such as neophytadiene, squalene, and β‐sitosterol. In conclusion, the vasorelaxant effect of EFCS on rat mesenteric arterial bed, which is dependent of muscarinic receptor activation, nitric oxide, and EDHF, can account for potential therapeutic use against high blood pressure related cardiovascular diseases.Keywords
Funding Information
- Université Sidi Mohamed Ben Abdellah
- Centre National pour la Recherche Scientifique et Technique (VPMA-2019-9)
This publication has 43 references indexed in Scilit:
- Extraction of High Quality DNA from Seized Moroccan Cannabis Resin (Hashish)PLOS ONE, 2013
- Is the cardiovascular system a therapeutic target for cannabidiol?British Journal of Clinical Pharmacology, 2013
- Endothelium-dependent vascular relaxation induced byGlobularia alypumextract is mediated by EDHF in perfused rat mesenteric arterial bedCanadian Journal of Physiology and Pharmacology, 2012
- Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stressFree Radical Biology and Medicine, 2011
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herbTrends in Pharmacological Sciences, 2009
- Chemotaxonomic Features Associated with Flavonoids of Cannabinoid-Free Cannabis (Cannabis sativasubsp.sativaL.) in Relation to hops (Humulus LupulusL.)Natural Product Letters, 2002
- Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar ratsBritish Journal of Pharmacology, 1996
- Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.Proceedings of the National Academy of Sciences, 1994
- The effects of perfusion rate and NG‐nitro‐L‐arginine methyl ester on cirazoline‐ and KCl‐induced responses in the perfused mesenteric arterial bed of ratsBritish Journal of Pharmacology, 1994
- Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proceedings of the National Academy of Sciences, 1987